Galectin-1 inhibitors and their potential therapeutic applications: a patent review.
2016
ABSTRACTIntroduction: Galectins have affinity for β-galactosides. Human galectin-1 is ubiquitously expressed in the body and its expression level can be a marker in disease. Targeted inhibition of galectin-1 gives potential for treatment of inflammatory disorders and anti-cancer therapeutics.Areas covered: This review discusses progress in galectin-1 inhibitor discovery and development. Patent applications pertaining to galectin-1 inhibitors are categorised as monovalent- and multivalent-carbohydrate-based inhibitors, peptides- and peptidomimetics. Furthermore, the potential of galectin-1 protein as a therapeutic is discussed along with consideration of the unique challenges that galectin-1 presents, including its monomer-dimer equilibrium and oxidized and reduced forms, with regard to delivering an intact protein to a pathologically relevant site.Expert opinion: Significant evidence implicates galectin-1’s involvement in cancer progression, inflammation, and host-pathogen interactions. Conserved sequence...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
169
References
40
Citations
NaN
KQI